Familial vesicoureteral reflux: testing replication of linkage in seven new multigenerational kindreds by Sanna-Cherchi S et al.
Familial Vesicoureteral Reflux: Testing Replication of
Linkage in Seven New Multigenerational Kindreds
Simone Sanna-Cherchi,*† Adam Reese,*‡ Terry Hensle,‡ Gianluca Caridi,§ Claudia Izzi,
You Yeun Kim,* Anita Konka,*, Luisa Murer,¶ Francesco Scolari, Roberto Ravazzolo,**††
Gian Marco Ghiggeri,§ Ali G. Gharavi*
*Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York,
New York; †Department of Clinical Medicine, Nephrology, and Health Science, University of Parma, Italy; ‡Department
of Urology, Columbia University College of Physicians and Surgeons, New York, New York; §Laboratory on
Pathophysiology of Uremia, G. Gaslini Institute, Genoa, Italy; Division and Chair of Nephrology, Spedali Civili,
University of Brescia, Italy; ¶Department of Pediatrics, University of Padua, Italy; **Laboratory of Molecular Genetics,
G. Gaslini Institute, and ††Department of Pediatrics and CEBR, University of Genoa, Italy
Vesicoureteral reflux (VUR) (OMIM %193000), a common cause of childhood renal failure, is strongly influenced by
hereditary factors. Familial VUR most closely conforms to autosomal-dominant inheritance, but because of variable pen-
etrance and expressivity, large multigenerational pedigrees tractable to linkage analysis have been difficult to ascertain. A
single genome-wide study of familial VUR has demonstrated linkage to chromosome 1p13, with 78% locus heterogeneity.
Previous studies in humans have also suggested loci on chromosomes 6p21, 10q26, and 19q13, whereas mutations in ROBO2
were recently reported in some patients with VUR. Replication of these studies was attempted in seven previously unde-
scribed families from Italy and the United States. Simulation studies, assuming 50% locus heterogeneity, showed that these
kindreds had 85% power to replicate linkage and 53% power to achieve genome-wide significance at candidate intervals.
Thirty-five markers on chromosomes 1p13, 3p12, 6p21, 10q26, and 19q13 were genotyped and analysis of linkage under a
variety of models was performed. Parametric analysis excluded linkage to all candidate loci under genetic homogeneity;
moreover, the data did not support statistically significant linkage under models of locus heterogeneity. Similarly, nonpara-
metric, allele-sharing analysis did not reveal any evidence of linkage at any of the loci tested. Thus, despite sufficient power,
linkage of familial VUR to previously reported candidate intervals could not be replicated. These data demonstrate substantial
genetic heterogeneity of VUR and suggest that mapping strategies relying on a large number of kindreds or single “loaded”
pedigrees will be most effective to achieve replication or detection of linkage.
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P rimary vesicoureteral reflux (VUR) (Online MendelianInheritance in Man [OMIM] %193000) occurs in ap-proximately 1% of infants and is caused by malfunction
of the vesicoureteral junction, resulting in retrograde flow of
urine from the bladder into the kidneys (1–4). Reflux nephrop-
athy, the renal disease associated with VUR, accounts for up to
25% of cases of ESRD in children (5). The biologic basis for this
disorder has not yet been defined. VUR presents in association
with other urogenital anomalies such as renal aplasia, multi-
cystic dysplastic kidney, duplicated ureters, or ureteropelvic
junction (UPJ) obstruction (6,7), suggesting a common patho-
genic link between these disorders. In addition, increased sib-
ling recurrence rates (30% to 50%) as well as parent–offspring
transmission strongly implicate hereditary factors in the devel-
opment of VUR (8,9). The severity of VUR varies between
affected individuals in a family, and the abnormalities often
improve or can entirely resolve with age, making complete
ascertainment of affected family members difficult. Moreover,
because the diagnosis often requires invasive procedures (e.g.,
voiding cystourethrography), asymptomatic individuals are
rarely screened. Nonetheless, based on available data, the pat-
tern of transmission for isolated VUR is most consistent with
multifactorial inheritance or autosomal-dominant inheritance
with reduced penetrance (7,10). Recently, one kindred display-
ing multiple urinary tract malformations that include VUR and
likely recessive inheritance has also been described (11).
In the only genome-wide linkage study reported to date,
Feather et al. studied seven European families with nonsyn-
dromic VUR and demonstrated linkage to a 20-cM interval on
chromosome 1p13 with a peak logarithm of odds (LOD) score
of 5.4 under a model of autosomal-dominant inheritance with
reduced penetrance and 78% of families linked (12). Studies of
humans with chromosomal abnormalities have also identified
candidate loci or genes on chromosomes 6p21 (CDC5L gene),
10q26, and 19q13 (USF2 gene) (13–17). Because mutations in
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PAX2 on 10q24 cause the renal coloboma syndrome, a rare
autosomal-dominant disease with kidney anomalies that in-
cludes VUR (15), this gene has also been proposed as a candi-
date. Linkage studies have also suggested the HLA locus on
6p21 in some families with VUR, UPJ obstruction, or renal
dysplasia (13,18). Finally, Lu et al. have recently reported mu-
tations in ROBO2 in some VUR patients (19).
Linkage to many of these loci (particularly the 1p13 interval)
has not been replicated in an independent, well-powered co-
hort, leaving open the question of how applicable these find-
ings are to other kindreds with VUR. Lander and Kruglyak
have suggested that linkage should be replicated in an inde-
pendent cohort to verify positive findings, to assess the level of
heterogeneity of the trait, and to evaluate the potential for type
I error in the initial reports (20). In such a replication test,
because one only tests linkage to a single chromosome segment
rather than the entire genome, significance at a point-wise P of
0.05 should provide significant evidence of linkage. Lander and
Kruglyak proposed the more stringent threshold P of 0.01 to
correct for multiple testing across a 20-cM interval (20).
We identified seven new multigenerational VUR families
with multiple affected members and tested whether they dem-
onstrate linkage to the candidate loci reported for humans on
chromosomes 1, 3, 6, 10, and 19. Despite considerable power,
we were unable to replicate linkage to any of the published
intervals, suggesting that heterogeneity of this trait may be
more significant than previously appreciated.
Materials and Methods
Patients
We recruited seven pedigrees with multiple individuals affected with
VUR (Figure 1). All families were ascertained through an index case
with VUR documented by a voiding cystourethrography (VCUG).
Family members were considered as affected based on the presence of
reflux documented by VCUG (29 cases), the diagnosis of childhood
ESRD in absence of obvious causes such as glomerulonephritis (two
cases) or documented recurrent urinary tract infections in a male child
before age 9 (one case). Two family members in K114 were diagnosed
by renal sonogram with UPJ obstruction but never underwent VCUG
testing. Because VCUG is an invasive test, our study could not recom-
mend this procedure to determine whether these two patients had
concurrent VUR. Nevertheless, these two individuals were considered
as affected because UPJ obstruction is a clear abnormality, and previous
studies have suggested that VUR and UPJ obstruction have a common
genetic cause (4,21). Affected individuals had no evidence of secondary
causes of VUR or syndromic abnormalities. Current practice involves
screening siblings of affected individuals. Thus, many members of the
youngest generations in this study had been previously screened by
VCUG. However, because VUR often improves or resolves with age,
only individuals younger than 6 years with a negative VCUG study
were classified as unaffected. All other individuals were classified as
phenotype unknown. All individuals gave informed consent and the
study protocol adhered to the Declaration of Helsinki and was ap-
proved by the Western Institutional Review Board and ethics commit-
tees at the University of Brescia and the Gaslini Institute.
Microsatellite Genotyping
Total genomic DNAwas isolated from peripheral white blood cells of
the patients and relatives using standard procedures. We genotyped
the patients for 35 microsatellite markers located within candidate
regions reported (Table 1). These markers were selected from the
genome-wide panel of the Marshfield Weber set 13 (http://www.
marshfieldclinic.org), but additional markers were added to increase
information, particularly on chromosomes 1 and 3. Altogether, we had
an average marker spacing of 8.1 cM at the candidate intervals, with an
average marker heterozygosity of 0.76.
Fluorescent dye-labeled primers were used to direct PCR at micro-
satellite loci. PCR products were resolved on a capillary sequencer
(SpectruMedix LLC, State College, PA), and genotypes were scored
using the GenoSpectrumV220 software (SpectruMedix LLC).
Analysis of Linkage
We performed pair-wise and multipoint analysis of linkage using the
FASTLINK 4.1 (22,23) and ALLEGRO 1.2c (24) programs, respectively.
Parametric analysis was performed under the model previously used to
map the first locus for isolated VUR (12): Affected-only analysis with an
autosomal-dominant inheritance, disease gene frequency of 0.01, and a
phenocopy rate of 0.01. Allele frequencies were calculated based on the
frequencies observed in the data set. We computed LOD scores under
models of genetic homogeneity (i.e., all families link to the same locus)
and genetic heterogeneity (a fraction of families link to the locus tested).
Calculation of LOD scores under genetic heterogeneity (HLOD) enables
detection of linkage in situations in which the same phenotype is
Figure 1. Pedigree structure of the seven kindreds studied.
Squares represent males, circles represent females. Black sym-
bols: affected individuals; white symbols: unaffected individu-
als (normal voiding cystourethrography [VCUG]); gray sym-
bols: affection status unknown. The symbols with double
contour are patients in whom ESRD developed. A line through
the symbols means the individual is deceased. *Individuals
genotyped for this study.
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produced by mutations in different genes (locus heterogeneity), such
that the genetic cause of disease differs between families. Linkage
analysis under heterogeneity is performed assuming that a proportion
of families () is linked to the marker tested, whereas the remaining
families are unlinked. The LOD score for each family is therefore
maximized over two parameters ( and the recombination fraction, ),
yielding the HLOD. The total HLOD at a given locus is calculated by
the sum of the HLOD from all of the kindreds studied. This analytic
method results in minimal expenditure of degrees of freedom and has
been shown to be a powerful tool for detection of linkage (25). In
addition, to avoid erroneous exclusion of a locus because of mis-
specification of the disease model, we performed nonparametric, allele-
sharing analysis using permissive scoring functions (exponential
model, with the “all” scoring function and equal weighting between
families) as implemented in ALLEGRO. Published thresholds for
genome-wide significance (LOD 3.3), replication (P  0.01), and
exclusion of linkage (LOD  2) were used (20). Studies exploring the
properties of the HLOD statistic suggested that an HLOD of approxi-
mately 1.2 corresponds to P  0.01 (25).
Because these thresholds have been obtained assuming analysis of a
large number of small pedigrees with an infinitely dense map, they
may not be pertinent to data sets that vary in pedigree structure and
information content. We therefore performed simulations to evaluate
the power of our pedigrees to detect linkage and obtain the empiric
thresholds for significance of our findings. We performed simulations
of genotypes with ALLEGRO, using the same family structure and
affection status as our VUR pedigrees, and specifying a 20-cM genetic
map with marker spacing and heterozygosities equivalent to those
used at our candidate intervals. To obtain the null distribution for our
linkage statistics, we first performed simulations of genotypes under
Table 1. Pairwise total LOD scores at different recombination fractions ()
Marker name Chr cM

0.0 0.01 0.05 0.1 0.2 0.3 0.4
GATA124C08N 1 129.37 0.33 0.28 0.13 0.04 0 0 0.01
GATA133A08Q 1 137.59 6.29 5.41 3.44 2.18 0.96 0.42 0.14
D1S1627 1 139.02 2.61 2.29 1.49 0.93 0.37 0.14 0.05
D1S2809 1 144.38 0.48 0.26 0.21 0.44 0.47 0.31 0.11
D1S534 1 151.88 0.55 0.45 0.19 0.03 0.06 0.05 0.02
D1S498 1 155.89 3.92 3.55 2.61 1.84 0.93 0.43 0.15
D1S2777 1 161.05 0 0.1 0.32 0.41 0.35 0.18 0.02
D1S1653 1 164.09 0.73 0.62 0.29 0.04 0.15 0.11 0.01
D1S1679 1 170.84 5.3 4.88 3.71 2.73 1.49 0.74 0.28
AAC023 3 94.20 5.29 4.25 2.31 1.20 0.31 0.04 0.01
D3S3653 3 107.19 4.15 3.16 1.61 0.84 0.22 0.02 0.03
D3S3681 3 109.22 8.22 6.87 4.31 2.78 1.30 0.61 0.23
D3S4529 3 112.42 2.76 2.25 1.29 0.68 0.15 0.00 0.01
D6S1959 6 34.23 1.91 1.59 0.8 0.3 0.09 0.15 0.08
D6S1022 6 44.41 2.59 2.35 1.63 1.07 0.46 0.18 0.05
D6S1051 6 50.75 3.93 3.5 2.34 1.48 0.54 0.12 0.04
D6S1017 6 63.28 0.88 0.7 0.29 0.06 0.06 0.02 0.03
D6S2410 6 73.13 1.77 1.48 0.82 0.41 0.06 0.03 0.02
D6S1053 6 80.45 3.52 3.1 2.09 1.39 0.65 0.29 0.11
D6S1031 6 88.63 1.74 1.58 1.12 0.72 0.24 0.05 0.00
D10S1432 10 93.92 1.54 1.3 0.7 0.29 0.05 0.11 0.07
D10S2327 10 100.92 0.89 0.59 0.03 0.24 0.36 0.29 0.16
D10S2470 10 112.58 6.02 5.39 3.81 2.64 1.29 0.55 0.15
D10S677 10 117.42 7.29 6.25 3.86 2.32 0.82 0.2 0.02
D10S1239 10 125.0 5.27 4.8 3.41 2.26 0.98 0.35 0.06
D10S1425 10 136.67 2.08 1.84 1.24 0.83 0.41 0.17 0.03
D10S1230 10 142.78 4.82 4.37 3.02 2.01 0.92 0.39 0.13
D10S1222 10 156.27 4.36 3.83 2.74 2.01 1.09 0.52 0.17
D10S1248 10 165.27 4.98 4.45 3.19 2.25 1.14 0.52 0.18
D19S714 19 42.0 6.06 5.27 3.37 2.06 0.73 0.17 0.02
D19S433 19 51.88 4.36 3.74 2.27 1.29 0.38 0.08 0.01
D19S559 19 68.08 3.77 3.3 2.11 1.3 0.52 0.2 0.07
D19S246 19 78.08 1.19 1.25 1.42 1.49 1.3 0.89 0.42
D19S589 19 87.66 0.24 0.24 0.21 0.17 0.09 0.04 0.01
D19S254 19 100.61 3.99 3.59 2.59 1.84 0.93 0.41 0.11
cM locations are based on the Marshfield map. LOD indicates logarithm of odds; Chr, chromosome.
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the hypothesis of no disease locus in the interval. We performed 1000
simulations to provide a solid estimate of the empiric LOD score
threshold corresponding to P  0.01. The simulated data were then
analyzed with ALLEGRO under the same model previously delineated
and HLOD were determined for each run. The HLOD calculated from
these 1000 simulated runs provide the distribution of the HLOD sta-
tistic under the hypothesis of no disease locus in the interval, the null
hypothesis. The HLOD in the top 1% and 5% of the distribution define
the point-wise empiric thresholds for type I error at P  0.01 and P 
0.05, respectively, and therefore constitute our thresholds for replica-
tion of linkage at P  0.01 and P  0.05 significance levels.
Inadequate study power may also hinder replication of original
linkage findings. Therefore, we used simulations to assess the power of
our study sample to detect linkage under various levels of locus het-
erogeneity. We simulated genotypes of our pedigree sample (1000
replicates) with the assumption of linkage under each of the following
conditions: (1) genetic homogeneity; (2) 50% locus heterogeneity; and
(3) 28.6% locus heterogeneity (two of seven families linked). We then
analyzed this second set of simulated pedigrees with ALLEGRO to
obtain the maximum and average expected LOD (eLOD) scores with
the models above. The fraction of LOD scores exceeding the thresholds
for genome-wide significance and linkage replication provided our
power to detect linkage with various levels of heterogeneity.
Results
Patients
We studied seven Caucasian pedigrees from Italy (K108,
K110, K114, K116) and the United States (K117, K118, K119). All
were ascertained via an index case with VUR documented by
VCUG. These seven multigenerational kindreds comprised 140
individuals (Figure 1); we collected DNA from 105 individuals.
In total, 41 individuals were classified as affected (36 based on
a positive VCUG, two based on the presence of ESRD, one by
the presence of documented recurrent urinary tract infections
in childhood, and two by UPJ obstruction documented by
sonogram). Eight patients were unaffected based on negative
VCUG performed at age 6 yr; 91 individuals were considered
as having unknown phenotype because they did not have a
clear phenotype (e.g., undocumented episodes of urinary tract
infections or history of enuresis) or were asymptomatic and
were not investigated by VCUG. There were 14 males and 27
females affected (male/female ratio  0.52). The age at the
diagnosis was 9.5  11 yr (range, 1 mo to 45 yr). Among those
affected, 14 patients underwent corrective surgery, ESRD de-
veloped in two patients, and one of them underwent kidney
transplantation. Consistent with previous reports, some indi-
viduals had associated urologic abnormalities: in K110, one
patient had renal stones; in K116, one patient had a pelvic
kidney; and in K117, one patient had a paraureteral diverticu-
lum. All of the affected individuals in K114 also had associated
UPJ obstruction documented by abdominal sonogram. Finally,
K117 is noteworthy because it has a theoretical maximal LOD
score 3 and can alone enable gene localization with genome-
wide significance.
In these pedigrees, male-to-male transmission and a higher
ratio of females to males argued against X-linked inheritance.
The absence of consanguinity and occurrence of the disease in
multiple generations made recessive inheritance unlikely. Con-
sistent with the literature, the pattern of transmission was most
consistent with multifactorial inheritance or an autosomal-
dominant inheritance with reduced penetrance (7).
Simulation Studies
In addition to using published criteria for replication, we
used simulations to establish empiric thresholds for replication
of linkage. In 1000 simulations under the null hypothesis of no
disease locus in the interval, we observed an HLOD 0.84 a
total of 10 times and an HLOD 0.51 a total of 50 times. These
data established the empiric threshold for replication of para-
metric linkage at P  0.01 and P  0.05, respectively (20). The
nonparametric LOD scores corresponding to these thresholds
were 1.88 and 1.3, respectively.
To determine the power of our sample to detect linkage, we
next performed simulations under the assumption of linkage
Table 2. Multipoint LOD scores in VUR families
Average
eLOD
LOD
1p13
LOD
3p12
LOD
6p21
LOD
6p21
LOD
10q24
LOD
10q26
LOD
19q13
Candidate gene ? ROBO2 HLA CDC5L PAX2 ? USF2
cM location 144 to 164 108 45 66 125 165 59
K 108 0.63 0.6 0.38 0.44 0.29 0.74 0.11 0.43
K 110 0.95 0.38 1.33 1.05 0.03 0.44 0.16 0.21
K 114 1.19 0.18 0.48 0.56 0.26 1.48 0.52 0.23
K 116 1.56 0.96 2.56 1.6 1.44 1.23 0.55 1.25
K 117 3.35 1.43 1.59 1.24 1.86 0.53 1.36 0.76
K 118 0.51 0.59 1.5 0.57 0.63 0.4 0.33 0.07
K 119 1.3 0.96 1.06 0.11 0.09 0.41 0.64 0.11
Total LOD (  100%) 9.49 3.18 8.14 4.69 3.84 4.43 3.13 2.06
HLOD (  50%) 3.45 0.46 1.37 0.96 0.69 1.06 0.86 0.45
Nonparametric LOD 8.15 0.74 0.02 0.01 0.31 0.06 0.29 0.06
Expected LOD (eLOD) for individual kindreds were obtained based on affected-only analysis with 1000 simulations,
assuming homogeneity. On chr01, LOD scores shown were obtained at the location with maximized HLOD (D1S1653, 164
cM). VUR indicates vesicoureteral reflux; HLOD, heterogeneity LOD.
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with various levels of genetic heterogeneity (1000 replicates
each). Under genetic homogeneity, the average parametric ex-
pected LOD for our kindreds was 1.4 (Table 2). For parametric
analysis, simulations yielded a maximum expected LOD score
of 11.14 (average 9.49  1.65) under homogeneity, 11.14 (aver-
age 3.45  2.34) under 50% locus heterogeneity, and 9.07 (av-
erage 1.71  1.83) under 28.6% locus heterogeneity (two fami-
lies out of seven linked). For nonparametric analysis, we
obtained a maximum expected LOD scores of 12.89 (average
8.15 1.52) under homogeneity, 9.96 (average 2.76 2.11) with
50% heterogeneity, and 8.67 (average 1.36  1.57) with 28.6%
heterogeneity. The threshold for replication (at P  0.01) was
exceeded in 100%, 85%, and 53% of simulated runs with ho-
mogeneity, 50% heterogeneity, and 28.6% heterogeneity, re-
spectively. These data indicate that our sample had ample
power not only to replicate linkage but also to achieve genome-
wide significance with at least 50% locus heterogeneity.
Analysis of Linkage
Tables 1 and 2 show the pair-wise and multipoint LOD scores
at the candidate intervals, respectively. Under genetic homoge-
neity, multipoint LOD scores were strongly negative, excluding
linkage to all candidate loci. In addition, our data do not
support statistically significant linkage to these loci under a
model of 50% genetic heterogeneity (negative HLOD at all
intervals). Varying the percentage of linked families to maxi-
mize the HLOD also did not achieve statistical significance at
any of these intervals, with a maximal HLOD of 0.55 on chro-
mosome 19 (D19S246) and 50% percent of pedigrees linked.
This peak score was obtained approximately 10 cM (16 Mb)
away from our candidate gene (USF2) and is significantly lower
than our empiric threshold for replication of linkage at the 1%
level. These results did not change significantly with alternative
analyses. As expected, lowering the disease allele frequency or
the phenocopy rate strengthened the evidence against linkage
at all intervals. Similarly, nonparametric analysis did not reveal
significant linkage to any of the candidate loci (maximum non-
parametric LOD of 0.74 on chromosome 1), demonstrating that
absence of linkage cannot be attributed to mis-specification of
disease model. Finally, secondary analyses with exclusion of
K114, a pedigree with associated UPJ obstruction, did not suf-
ficiently increase the LOD scores at candidate intervals to
achieve statistical significance.
Discussion
Replication studies are important components of genetic in-
vestigations because they help determine the level of heteroge-
neity of the trait and assess the potential for type 1 error (20,26).
Thus, although the estimated probability of false-positive find-
ings in genome scans is 0.05 when a threshold LOD score of
3.3 is used, Lander and Kruglyak emphasized that replication
studies should be also performed (20). Replication studies may
have difficulty in detecting linkage to reported loci because
initial positive reports tend to overestimate the genetic effect
(20,27). This bias occurs because initial reports tend to benefit
from random fluctuations that push the LOD score above sta-
tistical significance, whereas follow-up studies regress to the
true mean (20,27). Moreover, variation in methodology, ascer-
tainment criteria, and study population may also complicate
the ability to replicate initial findings (20,27). In the case of
VUR, one of the major obstacles for linkage studies is the
relative rarity of large pedigrees because of reduced penetrance
of the trait (7). Reduced penetrance necessitates affected-only
analysis and this constraint, combined with locus heterogene-
ity, diminishes the ability to assemble a well-powered cohort.
Our study, however, benefited from relatively large kindreds,
including one of the largest families reported to date (K117);
this kindred alone should be sufficiently large to support gene
localization at the genome-wide level. Moreover, our pedigrees
resembled Caucasian cohorts previously described, particularly
the one described by Feather et al. (12), and we used similar
ascertainment criteria and linkage models described in their
article. Our simulations indicated that we were well powered to
replicate linkage or achieve significance at the genome-wide
level, with a maximum expected LOD score of 11.14 under
homogeneity (for comparison we estimate the maximum ex-
pected LOD in the pedigrees by Feather et al. at approximately
8.7) (12). Nevertheless, despite analyses under many alternative
models, we found no evidence of linkage to loci previously
implicated in humans. Our best interval barely reached the
threshold for replication at P 0.05 on chromosome 19, but this
maximal score was achieved 16 Mb distal to the candidate gene
(USF2) and did not hold up to correction for multiple testing.
These data highlight the need to use stringent criteria to avoid
false replication of linkage.
The lack of replication is most likely caused by overestima-
tion of the risk attributable to previously reported loci and
substantial genetic heterogeneity of the trait. This heterogeneity
is demonstrated by human and animal studies indicating that
VUR can be caused by defects in a panel of genes expressed in
the lower urinary tract. For example, loss of the uroplakin III
gene causes VUR in the mouse (28); similarly, tissue-specific
ablation of calcineurin causes ureteropelvic obstruction (29).
Mice lacking either ROBO2 or its ligand, SLIT2, also have
urogenital developmental abnormalities that include supernu-
merary ureteric buds that remain inappropriately connected to
the nephric duct and failure of the ureters to connect to the
bladder (30). The number of mutant mice exhibiting renal de-
velopmental defects is rapidly growing, reflecting the intricate
biology of kidney development (31). These animal data high-
light the potential for genetic heterogeneity of human disease
and simultaneously provide a substantial list of candidate
genes for human VUR.
The candidate gene approach had generally met with limited
success in human VUR (e.g., screening of PAX2 or uroplakin
genes) (32,33). Lu et al. have, however, recently reported dis-
ruption of the ROBO2 gene in one patient with a balanced
translocation and a phenotype that included VUR; in addition,
mutational screening of patients with nonsyndromic VUR re-
vealed two nonconservative amino acid substitutions (19). The
full description of these patients is not available at the time of
writing this report, but these preliminary data indicate that
ROBO2 accounts for a small fraction of VUR cases (19). Con-
sistent with the rarity of ROBO2 mutation in humans, linkage
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to this locus was not supported in our seven kindreds. How-
ever, we expected to detect linkage to the 1p13 locus because it
accounted for disease in the majority (78%) of the families
Feather et al. studied (12). Among our kindreds, however, only
K119 showed a positive LOD score on chromosome 1p13, a
proportion (14.3%) insufficient to replicate linkage. Because we
had 85% power to replicate with 50% locus heterogeneity, our
data suggest that the chromosome 1p13 interval may account for
disease in smaller fraction of VUR kindreds, perhaps in as little as
15% and probably less than half of VUR families overall.
Together with the results of animal studies, our data raise the
potential that mutations in different genes each account for
disease in a small proportion of VUR families. In this scenario,
the search for VUR genes may be very complicated and might
have to rely on extensive screening of candidate genes in both
familial and sporadic cases. Linkage studies of the trait would
require a large number of average size pedigrees or would have
to rely on pedigrees such as K117 that have a sufficiently large
number of affected individuals to map a locus on their own. To
be successful, comprehensive studies combining all approaches
will likely be required. Accordingly, after testing the most
promising candidate loci reported in humans, we are now
proceeding with a genome-wide search to detect novel VUR
loci in our kindreds.
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